Dual-energy X-ray absorptiometry

RadNet and JVS SoCal Create ImagingWorks®, an Innovative Partnership to Launch Career Training Programs for Medical Imaging

Retrieved on: 
Thursday, February 15, 2024

(RadNet’s President and Chief Executive Officer), are helping close the opportunity gap in a specialized field that equips students for well-paying, meaningful careers in medical imaging.

Key Points: 
  • (RadNet’s President and Chief Executive Officer), are helping close the opportunity gap in a specialized field that equips students for well-paying, meaningful careers in medical imaging.
  • We are proud to partner with Karen and Howard Berger and RadNet on this special initiative,” said JVS SoCal CEO Jeff Carr.
  • “RadNet has been a leading employer-partner of JVS SoCal, especially in our CareerWork$ Medical® program, having hired dozens of graduates since 2019.
  • Through the new ImagingWorks® partnership, RadNet continues its legacy of community involvement and social responsibility,” concluded Mr. Carr.

Santhera Receives Approval for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy in the United Kingdom

Retrieved on: 
Friday, January 12, 2024

We are working towards making AGAMREE available to patients in the UK in the second half-year 2024, after NICE completes its pricing review.

Key Points: 
  • We are working towards making AGAMREE available to patients in the UK in the second half-year 2024, after NICE completes its pricing review.
  • Duchenne UK and our partner charities, Joining Jack and the Duchenne Research Fund, funded the early-stage clinical research to test vamorolone in patients, when no-one else would.
  • Santhera will continue to collect data to further characterize the long-term effectiveness and the broader safety differentiation of vamorolone.
  • This makes AGAMREE the first and only medicinal product fully approved in the EU and UK for DMD, and the first treatment approved for the treatment of DMD all three geographies.

StartUp Health Launches Global Alzheimer's Moonshot with Support from the Alzheimer's Drug Discovery Foundation (ADDF) and Gates Ventures

Retrieved on: 
Monday, January 8, 2024

SAN FRANCISCO, Jan. 8, 2024 /PRNewswire-PRWeb/ -- During the 42nd Annual J.P. Morgan Healthcare Conference week, StartUp Health, in partnership with the Alzheimer's Drug Discovery Foundation's (ADDF) Diagnostics Accelerator (DxA), and Gates Ventures, the private office of Bill Gates, announced the launch of the Alzheimer's Moonshot. This initiative aims to break down silos and foster meaningful collaboration between mission-aligned founders, funders, and partners, accelerating progress in preventing, managing, and curing Alzheimer's and related dementias through the support of entrepreneurial innovation. The Alzheimer's Moonshot is an invitation to Health Transformers, Alzheimer's funders, foundations, advocates, and innovators, as well as leading startups and research teams, to unite in pioneering comprehensive, collaborative approaches to Alzheimer's disease.

Key Points: 
  • SAN FRANCISCO, Jan. 8, 2024 /PRNewswire-PRWeb/ -- During the 42nd Annual J.P. Morgan Healthcare Conference week, StartUp Health , in partnership with the Alzheimer's Drug Discovery Foundation 's (ADDF) Diagnostics Accelerator (DxA), and Gates Ventures, the private office of Bill Gates, announced the launch of the Alzheimer's Moonshot.
  • "The ADDF welcomes the opportunity to partner with StartUp Health to launch the Alzheimer's Moonshot," notes Howard Fillit, MD, Co-Founder and Chief Science Officer at the ADDF.
  • Are you an academic founder, founder, startup or research team focused on Alzheimer's innovation who would like to join the Alzheimer's Moonshot?
  • To explore how your organization can become part of the Alzheimer's Moonshot (or one of our 14 global health moonshots) please reach out to us at [email protected] .

Santhera’s AGAMREE® (Vamorolone) Approved in the European Union for the Treatment of Duchenne Muscular Dystrophy

Retrieved on: 
Monday, December 18, 2023

In addition, patients who switched from a standard of care corticosteroid to AGAMREE maintained the efficacy benefit while recovering their growth and bone health.

Key Points: 
  • In addition, patients who switched from a standard of care corticosteroid to AGAMREE maintained the efficacy benefit while recovering their growth and bone health.
  • Santhera will continue to collect data to further characterize the long-term effectiveness and the broader safety differentiation of vamorolone.
  • Santhera announced on October 27, 2023 that the FDA approved AGAMREE oral suspension 40 mg/ml in the United States for the treatment of DMD in patients 2 years of age and older.
  • Catalyst Pharmaceuticals holds an exclusive license for AGAMREE in North America and plans to launch the product in the U.S. in Q1-2024.

WRQ Sciences and Superfluid Dx., Inc. Announce Completion of Oversubscribed Series A Financing in Breakthrough Alzheimer's Disease Diagnostic Company Superfluid Dx

Retrieved on: 
Wednesday, December 20, 2023

PALO ALTO, Calif., Dec. 20, 2023 /PRNewswire/ -- WRQ Sciences and Superfluid Dx, Inc., announced today the completion of an oversubscribed Series A financing led by WRQ Sciences. With this transaction, WRQ Sciences has acquired majority ownership in the Alzheimer's Disease (AD) diagnostics company, Molecular Stethoscope, Inc., which is now renamed Superfluid Diagnostics, Inc. The Alzheimer's Drug Discovery Foundation's (ADDF) Diagnostics Accelerator (DxA) participated in the Series A financing.

Key Points: 
  • PALO ALTO, Calif., Dec. 20, 2023 /PRNewswire/ -- WRQ Sciences and Superfluid Dx, Inc., announced today the completion of an oversubscribed Series A financing led by WRQ Sciences.
  • With this transaction, WRQ Sciences has acquired majority ownership in the Alzheimer's Disease (AD) diagnostics company, Molecular Stethoscope, Inc., which is now renamed Superfluid Diagnostics, Inc.
  • "One million Americans per year develop Alzheimer's Disease and the need for a fast and accurate diagnostic test is acute and expanding," said Gajus Worthington, Superfluid Diagnostics' CEO and Managing Director of WRQ Sciences.
  • The breakthrough work at Superfluid Diagnostics will transform the Alzheimer's Disease diagnostic landscape."

Alzheimer's Drug Discovery Foundation (ADDF) Announces Launch of SpeechDx, the First Study to Generate a Voice Database Paired with Clinical Data for Early Detection of Alzheimer's Disease

Retrieved on: 
Monday, October 23, 2023

NEW YORK, Oct. 23, 2023 /PRNewswire/ -- The Alzheimer's Drug Discovery Foundation's (ADDF) Diagnostic Accelerator (DxA) today announced the launch of SpeechDx, the first longitudinal study aimed at creating the largest repository of speech and voice data to help accelerate the detection, diagnosis and monitoring of Alzheimer's disease. Recorded voice samples from the study will be paired with clinical and biomarker data that can be leveraged by academic, biotech, and industry partners to develop algorithms for the creation of new speech biomarkers.

Key Points: 
  • SpeechDx is poised to develop a paired voice and clinical database that will provide the research community with harmonized data needed to generate speech-based diagnostic algorithms.
  • Study participants will be given handheld tablets with the pre-installed SpeechDx app to capture their voice data.
  • The use of this warehouse of data will be fundamental for the development of new and renewable digital voice biomarkers.
  • Additionally, each participant's voice recording will be paired with clinical data and harmonized across all sites.

Santhera Receives Positive CHMP Opinion Recommending Approval of AGAMREE® (vamorolone) for the Treatment of Duchenne Muscular Dystrophy

Retrieved on: 
Friday, October 13, 2023

Santhera plans for a first commercial launch in Germany in Q1-2024, subject to approval by the EC.

Key Points: 
  • Santhera plans for a first commercial launch in Germany in Q1-2024, subject to approval by the EC.
  • “We are thrilled about the CHMP’s positive opinion, which recognizes the urgent medical need for an effective and well tolerated treatment for this devastating disease.
  • “We are very excited about the positive opinion from the European Medicines Agency,” declared Ezio Magnano, President of Parent Project Italy.
  • A marketing authorization decision from the EC is expected within approximately two months of the positive CHMP opinion.

Fujitsu and iSurgery launch bone health promotion project in Japan with Jikei University School of Medicine aiming for early detection of osteoporosis

Retrieved on: 
Tuesday, September 26, 2023

Regardless of the results of the evaluation, the project team will also provide health guidance for prevention by utilizing the basic knowledge on bone health provided by the Jikei University School of Medicine.

Key Points: 
  • Regardless of the results of the evaluation, the project team will also provide health guidance for prevention by utilizing the basic knowledge on bone health provided by the Jikei University School of Medicine.
  • In Japan, where the demographic trends mean have led to a graying population, there are an estimated 12.8 million people with osteoporosis.
  • The employees' understanding of the course was 96.3%, so the bone density test proved to be effective as a countermeasure against bone health problems.
  • Target group: Approximately 30,000 employees of the Fujitsu Group received health examinations at the Fujitsu healthcare center in Kawasaki.

Carson Valley Health and Gilbane Building Company Celebrate Topping Out Milestone

Retrieved on: 
Friday, July 14, 2023

GARDNERVILLE, Nev., July 14, 2023 /PRNewswire-PRWeb/ -- Gardnerville, Nevada – July 14, 2023 – Carson Valley Health (CVH) and Gilbane Building Company gathered today along with local leaders to celebrate the topping-out milestone for the hospital addition in Gardnerville, Nevada.

Key Points: 
  • GARDNERVILLE, Nev., July 14, 2023 /PRNewswire-PRWeb/ -- Gardnerville, Nevada – July 14, 2023 – Carson Valley Health (CVH) and Gilbane Building Company gathered today along with local leaders to celebrate the topping-out milestone for the hospital addition in Gardnerville, Nevada.
  • "We are proud to support our growing community with the major expansion of Carson Valley Health," said Rich Arndt, Project Executive for Gilbane Building Company.
  • "Marking this milestone with our community and staff that have watched this expansion with us since the groundbreaking in October 2021 is exciting," said Jeff Prater, Carson Valley Health CEO.
  • In the past five years, the health needs of the Carson Valley community have changes, and Carson Valley Health has simultaneously experienced growth in nearly every healthcare service provided.

BMI is out. BFI is in. Why BodySpec created a better way to measure your health.

Retrieved on: 
Tuesday, April 18, 2023

BodySpec DEXA Scans are the best way to track true body composition and set your health baseline.

Key Points: 
  • BodySpec DEXA Scans are the best way to track true body composition and set your health baseline.
  • Using over 200,000 real scans from our database, we show that BMI and healthy body composition are not well correlated.
  • Incorporating body fat as a variable, BFI is a better representation of our real health and the risk of developing chronic disease down the line.
  • “We quickly realized that the data we collected could, in aggregate, add so much value to the way we measure health risks,” said Roy Shi, CEO at BodySpec.